Evidence map›Paper›PMID 34786494›Full record

ArticleBiochemistry and biophysics reports2021

Two distinct phenotypes of immunologically hot gastric cancer subtypes.

Noriyuki Saito, Yukari Kobayashi, Koji Nagaoka, Yoshihiro Kushihara, Yasuyoshi Sato, Ikuo Wada, Kazuhiro Kakimi, Yasuyuki Seto

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biochemistry and biophysics reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Noriyuki SaitoDepartment of Gastrointestinal Surgery, The University of Tokyo Graduate School of Medicine, Tokyo 113-8655, Japan.
Yukari KobayashiDepartment of Immunotherapeutics, The University of Tokyo Hospital, Tokyo 113-8655, Japan.
Koji NagaokaDepartment of Immunotherapeutics, The University of Tokyo Hospital, Tokyo 113-8655, Japan.
Yoshihiro KushiharaDepartment of Immunotherapeutics, The University of Tokyo Hospital, Tokyo 113-8655, Japan.
Yasuyoshi SatoDepartment of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan.
Ikuo WadaDepartment of Surgery, Tokyo Metropolitan Bokutoh Hospital, Tokyo 130-8575, Japan.
Kazuhiro KakimiDepartment of Immunotherapeutics, The University of Tokyo Hospital, Tokyo 113-8655, Japan.
Yasuyuki SetoDepartment of Gastrointestinal Surgery, The University of Tokyo Graduate School of Medicine, Tokyo 113-8655, Japan.
University of Tokyo Hospital · JPThe University of Tokyo · JPThe Cancer Institute Hospital · JPTokyo Metropolitan Bokutoh Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An in-depth understanding of the tumor microenvironment (TME) is required for the development of improved combination immunotherapies for gastric cancer. Recently, we classified these cancers into four main types defined by their immunological attributes, namely Hot 1, Hot 2, Intermediate and Cold. Of these, the T cell-inflamed "Hot" tumors were further divided into Hot 1 and Hot 2 with different clinical outcomes. Thus, overall survival and progression-free survival of patients with Hot 1 tumors were shorter than with Hot 2. In the present study, we re-evaluated RNA-Seq data of 6 Hot 1 and 6 Hot 2 gastric cancers to elucidate the underlying reason for the poor prognosis and T cell dysfunction in the former. In addition, 56 Hot 1 and 27 Hot 2 tumors in The Cancer Genome Atlas (TCGA) were analyzed. We report that single sample Gene Set Enrichment Analysis (ssGSEA) and differential gene expression analysis identified differences between Hot 1 and Hot 2 tumors involved in metabolism and cell adhesion pathways. Therefore, it is suggested that strategies to modulate active metabolism in Hot 1 tumors should be integrated into the treatment of these gastric cancers.

Indexed as

Gastric cancerHot tumorRNA-SeqT cell-inflamedTumor immunity

Identifiers

PMID34786494
PMCPMC8579120
OpenAlexW3208139011

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.